CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
4.560
0.00 (0.00%)
At close: Apr 2, 2026, 4:00 PM EDT
4.557
-0.003 (-0.07%)
After-hours: Apr 2, 2026, 7:31 PM EDT
CytomX Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts that cover CytomX Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $12.1, which forecasts a 165.35% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $17.
Price Target: $12.1 (+165.35%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CytomX Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 7 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $10 → $12 | Buy | Maintains | $10 → $12 | +163.16% | Mar 23, 2026 |
| Barclays | Barclays | Buy Maintains $10 → $16 | Buy | Maintains | $10 → $16 | +250.88% | Mar 19, 2026 |
| Jefferies | Jefferies | Strong Buy Maintains $8 → $16 | Strong Buy | Maintains | $8 → $16 | +250.88% | Mar 18, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $10 → $15 | Strong Buy | Maintains | $10 → $15 | +228.95% | Mar 18, 2026 |
| Wedbush | Wedbush | Buy Maintains $6 → $11 | Buy | Maintains | $6 → $11 | +141.23% | Mar 17, 2026 |
Financial Forecast
Revenue This Year
24.63M
from 76.20M
Decreased by -67.68%
Revenue Next Year
29.25M
from 24.63M
Increased by 18.75%
EPS This Year
-0.39
from -0.15
EPS Next Year
-0.38
from -0.39
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 84.0M | 88.9M | |||
| Avg | 24.6M | 29.2M | |||
| Low | 3.9M | 2.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 10.2% | 261.1% | |||
| Avg | -67.7% | 18.8% | |||
| Low | -94.9% | -92.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.22 | -0.20 | |||
| Avg | -0.39 | -0.38 | |||
| Low | -0.53 | -0.53 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.